Skip to main content
Top

29-10-2024 | Type 1 Diabetes | Case Report

Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer

Authors: Iwaho Hazekawa, Norio Ishii

Published in: Diabetology International

Login to get access

Abstract

A 58-year-old woman with a body mass index of 26.4 kg/m2 was referred because of high glycated hemoglobin (HbA1c) at a medical checkup. Her anti-glutamic acid decarboxylase antibody (GADA) titer was positive (16.0 U/mL; normal < 5.0 U/mL). Her HbA1c was controlled at 6.4%–7.5% using metformin, ipragliflozin, and sitagliptin. Two-and-a-half years later, she was diagnosed with endometrial cancer with pelvic lymph node metastasis and underwent surgery followed by chemotherapy with carboplatin and paclitaxel, then carboplatin and docetaxel. However, owing to enlargement of the metastatic nodules, combination therapy with pembrolizumab and lenvatinib (pem + len) was initiated (DAY 1). On DAY 36, her plasma glucose (PG) concentration was high; therefore, insulin degludec was administered once daily and self-monitoring of blood glucose commenced. On DAY 50, her PG and HbA1c were 509 mg/dL and 10.2%, respectively, and her insulin therapy was changed to a basal–bolus. Urinary ketones were negative. Treatment with pem + len was continued without interruption. Her GADA was negative 3 months before starting pem + len (DAY − 119), but was high (234 U/mL) on DAY 50, and then negative on DAYs 345 and 670. Her serum C-peptide concentration gradually decreased, but it did not disappear (DAYs − 119, 50, 156, 345, 607 and 670: 2.49, 1.80, 0.90, 0.21, 0.85 and 0.65 ng/mL, respectively). Human leukocyte antigen analysis revealed two susceptibility haplotypes (DRB1*04:05-DQB1*04:01-DPB1*02:01 and DRB1*04:05-DQB1*04:01-DPB1*05:01) for type 1 diabetes (T1D). This case is notable in that pembrolizumab-related T1D progressed more slowly than previously reported, and lenvatinib may have contributed to this delay.
Literature
1.
go back to reference Wu L, Tsang V, Menzies AM, Sasson SC, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023;46:1292–9.CrossRefPubMed Wu L, Tsang V, Menzies AM, Sasson SC, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023;46:1292–9.CrossRefPubMed
2.
go back to reference de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019;181:363–74.CrossRefPubMedPubMedCentral de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019;181:363–74.CrossRefPubMedPubMedCentral
3.
go back to reference Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T, Consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell deth-1 therapy. Diabetes Int. 2019;10:58–66. Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T, Consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell deth-1 therapy. Diabetes Int. 2019;10:58–66.
4.
go back to reference Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version). Diabetol Int. 2024;15:1–4.CrossRefPubMed Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version). Diabetol Int. 2024;15:1–4.CrossRefPubMed
5.
go back to reference Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H, Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.CrossRefPubMed Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H, Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.CrossRefPubMed
6.
go back to reference Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma. Diabetol Int. 2020;12:234–40.CrossRefPubMedPubMedCentral Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma. Diabetol Int. 2020;12:234–40.CrossRefPubMedPubMedCentral
7.
go back to reference Inaba H, Morita S, Kosugi D, Asai Y, Kaido Y, Ito S, Hirobata T, Inoue G, Yamamoto Y, Jinnin M, Kimura H, Ota M, Okudaira Y, Nakatani H, Kobayashi T, Iwama S, Arima H, Matsuoka T. Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Front Immunol. 2023;14:1165004. https://doi.org/10.3389/fimmu.2023.1165004.CrossRefPubMedPubMedCentral Inaba H, Morita S, Kosugi D, Asai Y, Kaido Y, Ito S, Hirobata T, Inoue G, Yamamoto Y, Jinnin M, Kimura H, Ota M, Okudaira Y, Nakatani H, Kobayashi T, Iwama S, Arima H, Matsuoka T. Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Front Immunol. 2023;14:1165004. https://​doi.​org/​10.​3389/​fimmu.​2023.​1165004.CrossRefPubMedPubMedCentral
8.
go back to reference Liao PF, Peng TR, Wu TW, Hu YH. Lenvatinib-associated fulminant type 1 diabetes mellitus. Am J Ther. 2023;30:e561–3.CrossRefPubMed Liao PF, Peng TR, Wu TW, Hu YH. Lenvatinib-associated fulminant type 1 diabetes mellitus. Am J Ther. 2023;30:e561–3.CrossRefPubMed
9.
go back to reference Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016;65:765–7.CrossRefPubMedPubMedCentral Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016;65:765–7.CrossRefPubMedPubMedCentral
10.
go back to reference Matsumura K, Nagasawa K, Oshima Y, Kikuno S, Hayashi K, Nishimura A, Okubo M, Uruga H, Kishi K, Kobayashi T, Mori Y. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab. J Diabetes Investig. 2018;9:438–41.CrossRefPubMed Matsumura K, Nagasawa K, Oshima Y, Kikuno S, Hayashi K, Nishimura A, Okubo M, Uruga H, Kishi K, Kobayashi T, Mori Y. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab. J Diabetes Investig. 2018;9:438–41.CrossRefPubMed
11.
go back to reference Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in ‘anti-programmed cell death protein 1 antibody-induced’ fulminant type 1 diabetes. J Diabetes Investig. 2018;9:448–9.CrossRefPubMedPubMedCentral Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in ‘anti-programmed cell death protein 1 antibody-induced’ fulminant type 1 diabetes. J Diabetes Investig. 2018;9:448–9.CrossRefPubMedPubMedCentral
12.
go back to reference Nishimura A, Matsumura K, Kikuno S, Nagasawa K, Okubo M, Mori Y, Kobayashi T. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.CrossRefPubMedPubMedCentral Nishimura A, Matsumura K, Kikuno S, Nagasawa K, Okubo M, Mori Y, Kobayashi T. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.CrossRefPubMedPubMedCentral
14.
go back to reference Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26:643–56.CrossRefPubMed Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26:643–56.CrossRefPubMed
16.
go back to reference Ak S, Patel SS, Patel S, Parikh P. Future treatment of diabetes - tyrosine kinase inhibitors. J Diabetes Metab Disord. 2022;22:61–71.CrossRef Ak S, Patel SS, Patel S, Parikh P. Future treatment of diabetes - tyrosine kinase inhibitors. J Diabetes Metab Disord. 2022;22:61–71.CrossRef
17.
go back to reference Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895–900.CrossRefPubMedPubMedCentral Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895–900.CrossRefPubMedPubMedCentral
18.
go back to reference Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008;19:824–5.CrossRefPubMed Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008;19:824–5.CrossRefPubMed
19.
go back to reference Huda MS, Amiel SA, Ross P, Aylwin SJ. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care. 2014;37:e87–8.CrossRefPubMed Huda MS, Amiel SA, Ross P, Aylwin SJ. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care. 2014;37:e87–8.CrossRefPubMed
20.
go back to reference Salaroli A, Loglisci G, Serrao A, Alimena G, Breccia M. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. Ann Hematol. 2012;91:1823–4.CrossRefPubMed Salaroli A, Loglisci G, Serrao A, Alimena G, Breccia M. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. Ann Hematol. 2012;91:1823–4.CrossRefPubMed
21.
go back to reference Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Greevec Trial Study Group. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:502–14.CrossRefPubMedPubMedCentral Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Greevec Trial Study Group. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:502–14.CrossRefPubMedPubMedCentral
22.
go back to reference Awata T, Shimada A, Maruyama T, Oikawa Y, Yasukawa N, Kurihara S, Miyashita Y, Hatano M, Ikegami Y, Matsuda M, Niwa M, Kazama Y, Tanaka S, Kobayashi T. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.CrossRefPubMedPubMedCentral Awata T, Shimada A, Maruyama T, Oikawa Y, Yasukawa N, Kurihara S, Miyashita Y, Hatano M, Ikegami Y, Matsuda M, Niwa M, Kazama Y, Tanaka S, Kobayashi T. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.CrossRefPubMedPubMedCentral
23.
go back to reference Wang X, Zheng P, Huang G, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: promising new agents for autoimmune diabetes. Clin Exp Med. 2018;18:473–80.CrossRefPubMed Wang X, Zheng P, Huang G, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: promising new agents for autoimmune diabetes. Clin Exp Med. 2018;18:473–80.CrossRefPubMed
24.
go back to reference Gurgel Penaforte-Saboia J, Cour CEB, Vasconcelos Albuquerque N, Lauanna Lima Silva V, da Cunha Bitar, Olegario N, Oliveira Fernandes V, Montenegro Junior RM. Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus. Diabetes Metab Syndr Obes. 2021;14:565–73.CrossRefPubMedPubMedCentral Gurgel Penaforte-Saboia J, Cour CEB, Vasconcelos Albuquerque N, Lauanna Lima Silva V, da Cunha Bitar, Olegario N, Oliveira Fernandes V, Montenegro Junior RM. Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus. Diabetes Metab Syndr Obes. 2021;14:565–73.CrossRefPubMedPubMedCentral
25.
go back to reference Hirata T, Shimada A, Morimoto J, Maruyama T. Slowly progressive type 1 diabetes treated with metformin for five years after onset. Intern Med. 2013;52:2635–7.CrossRefPubMed Hirata T, Shimada A, Morimoto J, Maruyama T. Slowly progressive type 1 diabetes treated with metformin for five years after onset. Intern Med. 2013;52:2635–7.CrossRefPubMed
26.
go back to reference The Diabetes Control and Complication Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complication trial. Ann Intern Med. 1998;128:517–23.CrossRef The Diabetes Control and Complication Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complication trial. Ann Intern Med. 1998;128:517–23.CrossRef
Metadata
Title
Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer
Authors
Iwaho Hazekawa
Norio Ishii
Publication date
29-10-2024
Publisher
Springer Nature Singapore
Published in
Diabetology International
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00771-0

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Live: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more